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ABSTRACT
Introduction Existing mobility endpoints based on functional 
performance, physical assessments and patient self- reporting 
are often affected by lack of sensitivity, limiting their utility 
in clinical practice. Wearable devices including inertial 
measurement units (IMUs) can overcome these limitations 
by quantifying digital mobility outcomes (DMOs) both during 
supervised structured assessments and in real- world 
conditions. The validity of IMU- based methods in the real- 
world, however, is still limited in patient populations. Rigorous 
validation procedures should cover the device metrological 
verification, the validation of the algorithms for the DMOs 
computation specifically for the population of interest and in 
daily life situations, and the users’ perspective on the device.
Methods and analysis This protocol was designed to 
establish the technical validity and patient acceptability of the 
approach used to quantify digital mobility in the real world by 
Mobilise- D, a consortium funded by the European Union (EU) 
as part of the Innovative Medicine Initiative, aiming at fostering 
regulatory approval and clinical adoption of DMOs.
After defining the procedures for the metrological verification 
of an IMU- based device, the experimental procedures for 
the validation of algorithms used to calculate the DMOs 
are presented. These include laboratory and real- world 
assessment in 120 participants from five groups: healthy older 
adults; chronic obstructive pulmonary disease, Parkinson’s 
disease, multiple sclerosis, proximal femoral fracture and 
congestive heart failure. DMOs extracted from the monitoring 
device will be compared with those from different reference 
systems, chosen according to the contexts of observation. 
Questionnaires and interviews will evaluate the users’ 
perspective on the deployed technology and relevance of the 
mobility assessment.
Ethics and dissemination The study has been granted ethics 
approval by the centre’s committees (London—Bloomsbury 
Research Ethics committee; Helsinki Committee, Tel Aviv 
Sourasky Medical Centre; Medical Faculties of The University of 
Tübingen and of the University of Kiel). Data and algorithms will 
be made publicly available.
Trial registration number ISRCTN (12246987).
Strengths and limitations of this study
 ► A multidisciplinary approach was implemented to 
define a protocol for the validation of tools for mobil-
ity monitoring, covering aspects related to devices, 
algorithms and users.
 ► A set of rigorous quality assurance procedures have 
been established to allow for the creation of a high- 
quality annotated dataset to foster development in 
the field of digital mobility monitoring.
 ► Mobility data will be collected in the laboratory and 
in the real- world for five different cohorts of slow- 
walkers and subsequently will be made publicly 
available at the end of the study.
 ► The multistage and multidevice experimental pro-
cedures required by this validation study can be 
extremely challenging for both the participants and 
the assessors.
 ► For the laboratory acquisitions, the level of agree-
ment between the gold standard and the inertial 
sensor devices might be affected by the limitations 
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INTRODUCTION
The ability to move is a key contributor to physical, mental 
and social well- being, which is in line with the WHO’s 
definition of health.1 However, the study of mobility has 
received relatively little attention, except for diseases char-
acterised by specific mobility dysfunction. The increasing 
longevity of the world’s population, together with 
prolonged survival of many patients with long term condi-
tions, means that more people are suffering from loss of 
mobility, which in turn is a major contributing factor to 
a loss of independence.2 3 This has a considerable and 
growing personal, societal and economic impact. Efforts 
to mitigate this loss of mobility are an increasing priority 
and promising interventions are now under investigation.
Existing mobility endpoints based on performance, 
patient self- reporting and one- off assessment are 
resource- intensive and lack sensitivity,4 which limits ther-
apeutic development and clinical management. A novel 
approach is needed that is low cost, simple, accurate and 
that can be used in the real world, including the home 
and the community.
Poor gait, especially slow walking, is a key deter-
minant of mobility loss. It is associated with greater 
mortality, morbidity, cognitive decline, dementia and 
fall risk.2 3 Quantifying gait related mobility outcomes, 
including features such as step/stride duration and their 
variability, walking speed and asymmetry features is well 
established in supervised instrumented assessments.
Wearable devices including inertial measurement units 
(IMUs) that allow digital mobility outcomes (DMOs) to 
be described are leading the transition from a laboratory- 
based assessment of mobility (mobility capacity), to 
continuous, unsupervised monitoring of mobility in daily 
life conditions (mobility performance). Nonetheless, the 
validity of IMU- based methods to characterise real- world 
mobility, and gait in particular, is still limited, especially in 
populations suffering from pathological conditions. This 
is because measuring real- world gait is far from simple 
or straightforward. In addition, complex factors arise 
from multiple sources that influence outcome measures, 
including disease characteristics, patient specific habits, 
environment/context and the purpose of walking. All 
these factors limit the validity of existing algorithms 
developed to quantify targeted DMOs.5 Additionally, vali-
dation should include simultaneous evaluation6 of the 
participants perception and acceptability of the device7 
as well as aspects related to wearability and usability.8 9 
Finally, a separate assessment of the metrological perfor-
mance of the sensors contained in the adopted device 
is required. All these validation steps need to be taken 
before the DMOs and the associated technologies can 
be effectively used for clinical4 and regulatory10 purposes 
(see figure 1 for summary).
In this paper, we present the comprehensive, multi-
stage protocol deployed in the technical validation study 
(TVS) that we have developed as part of the IMI2- JU- 
funded Mobilise- D project (Number 820820),11 that aims 
to validate a new digital method for remote monitoring 
of mobility. In particular, this multistage protocol aims to: 
(1) verify the metrological performance of the sensors 
included in a IMU- based monitoring device, using a 
procedure that could be replicated on any device; (2) 
establish the validity and reliability12 of the DMOs esti-
mated by the algorithms using data from an IMU- based 
device, taking into accounts the effects of populations 
(eg, healthy adults, patients with various conditions), 
locomotor activities (simple straight walking vs complex 
walking tasks), contexts (lab based vs real world), dura-
tions (device wearing time, DMOs hourly and daily fluc-
tuations, etc) and contextual confounding factors (such 
as location of walks, weather, use of walking aids, etc); and 
(3) establish participants’ and assessors’ opinions on the 
usability and acceptability of the monitoring devices that 
will be deployed.
This protocol will provide the stakeholders, the first 
comprehensive, multimodal solution to validate real- 
world mobility. Notably, the protocol described here has 
been accepted by the European Medical Agency13 as part 
of the Mobilise- D process for the regulatory qualification 
of real- world mobility performance biomarkers in Parkin-
son’s disease.10
METHODS
The monitoring device that will be used in this study to 
collect mobility data is the DynaPort MM+ IMU (McRob-
erts, table 1). In a trade- off between usability, accuracy and 
ability to provide DMOs for both at step and stride level, 
this is attached to the lower back via an elastic waistband 
and Velcro strap. The validity of algorithms to accurately 
estimate DMOs in the real- world will be investigated in 
120 participants including: healthy older adults (HA) and 
in five clinical cohorts (chronic obstructive pulmonary 
disease, COPD; Parkinson’s disease, PD; multiple scle-
rosis, MS; proximal femoral fracture, PFF; and congestive 
heart failure, CHF), chosen as presenting a variety of gait 
and mobility features.4 The usability and acceptability of 
the device from the perspective of the participants and 
the assessors involved in the study will be established via 
interviews and questionnaires.
Figure 1 Concurrent domains to be assessed as part of 
a technical validation of digital mobility outcomes (DMOs) 
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Verification of the metrological performances of the device
Verifying the performance of a device needs a robust 
and comprehensive metrological characterisation of all 
the sensors that it embeds. This requires a series of stan-
dardised procedures (spot- checks) to be implemented 
to ensure accuracy of raw data that will be used as input 
to the algorithms. Table 1 shows the sensing characteris-
tics of the device used in this study, the Dynaport MM+ 
(dimensions: 106.6×58×11.5 mm, size: 55 g).
According to Institute of Electrical and Electronics Engi-
neers Standard for Sensor Performance Parameter Definitions 
(IEEE 2700–2017)14 a number of parameters are needed 
to characterise the metrological performance of the 
accelerometer, gyroscope and magnetometer included in 
an IMU. These parameters can be computed under both 
static and dynamic conditions. The main noise parame-
ters used are the first (mean value) and second (variance) 
order statistics, and the root Allan variance parameters of 
noise.15 16 The parameters related to the first and second 
order statistics of noise can also be estimated by means of 
a short static acquisition (the minimum length of each 
acquisition is defined by IEEE standard for each sensor). 
These short static acquisitions can be performed simply 
using a plastic cube, where the device can be properly 
secured and then each of the three sensors’ coordinate 
axes x, y and z are in turn aligned with the direction of 
gravity (g) as well as its opposite direction (six combina-
tions, figure 2). The root Allan variance parameters are 
instead computed over a long static acquisition.17 Typi-
cally, the acquisitions are performed over a period of 4–8 
hours.15 16 All the static acquisitions should be carried out 
at a constant temperature of 25°C.
In comparison to a static acquisition, characterising 
the dynamic metrological performance of the sensors 
embedded in an IMU is less straightforward, since the 
metrological standards provided by IEEE describe a 
sequence of operations requiring an expensive and 
complex testing instrumentation. However, various alter-
natives have been proposed in the literature. The accu-
racy of a gyroscope can be quantified during a single- axis 
rotation by a known angle by computing the ideal angular 
velocity and comparing it to the average measured angular 
velocity.18 19 This procedure should be performed using a 
rotation plate with a rotating speed comparable to what 
is encountered during human gait (~200°/s) (figure 2).
The tests described above will be performed on 35 
different DynaPort MM+ devices deployed in the study. 
This will allow conformity with manufacturer indications 
to be verified, highlight the need for sensor recalibra-
tions and provide benchmark standards for any device 
with equivalent sensing capacity. In turn, this will allow 
any device with an equivalent or superior solution to be 
used, in order to facilitate broader adoption of validated 
algorithms and cope with a continuously changing hard-
ware landscape.
Protocol for validation of the algorithms
Several algorithms to detect the DMOs from a single 
device have been implemented according to agreed defi-
nitions20 and based on existing literature. At this time, 
these algorithms are being concurrently validated using 
the approach described by Bonci et al6 using pre- existing 
datasets, which mostly include lab- based observations 
only. Following this selection process, the best performing 
algorithms will be assessed using the data captured with 
the protocol here described.
Ethics and dissemination
This multicentre study is sponsored and coordinated 
by The Newcastle upon Tyne Hospitals National Health 
Service (NHS) Foundation Trust, UK. Participants will 
be recruited in five sites across Europe: Tel Aviv Sourasky 
Medical Center, Israel (ethics approval granted by the 
Helsinki Committee, Tel Aviv Sourasky Medical Center, 
Tel Aviv, Israel, 0551- 19TLV), Robert Bosch Foundation 
for Medical Research, Germany (ethics approval granted 
by the ethical committee of the medical faculty of The 
University of Tübingen, 647/2019BO2), University of 
Kiel, Germany (ethics approval granted by the ethical 
committee of the medical faculty of Kiel University, 
D438/18), The Newcastle upon Tyne Hospitals NHS 
Foundation Trust, UK and Sheffield Teaching Hospitals 
NHS Foundation Trust, UK (ethics approval granted by 
London—Bloomsbury Research Ethics committee, 19/
LO/1507).
Table 1 Characteristics of the sensors included in the DynaPort MM+ device
Sensor Sampling frequency Sensor range Sensor resolution
Tri- axial accelerometer 100 Hz ±8 g 1 mg (at ±8 g)
Tri- axial gyroscope 100 Hz ±2000 dps 70 mdps (at ±2000 dps)
Figure 2 Testing configurations used during (A) short static 
(plexiglass cube and device) and (B) dynamic (turntable and 
device) acquisitions. Marks (in red) are applied on both on the 
turntable and on the base to identify start/end, which have to 
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As per the study register (ISRCTN, 12246987), the 
data collection was originally planned to start in April 
2020 and last 6 months. The pandemic situation meant 
that the study started in July 2020 and is now planned to 
finish in September 2021. All experimental procedures 
are constantly monitored and revised as needed to ensure 
full compliance with COVID19- related health and safety 
measures and for safeguarding of both the study partici-
pants and the assessors. The data collected as part of this 
protocol will be made publicly available together with the 
algorithms used to process the data.
Participants
A convenience sample of 120 participants will be 
recruited via their clinical care team or research regis-
ters to represent the five disease cohorts (COPD, PD, 
MS, PFF and CHF), as well as HA. Twenty participants 
will be recruited for each cohort. Each cohort will be 
recruited across multiple sites to ensure generalisability 
(eg, differing cultures and contexts). Inclusion and exclu-
sion criteria, grouped by total cohort and disease cohort, 
are summarised in table 2. Given the novelty of the data, 
rather than on a power calculation the sample size of 120 
has been initially defined according to Consensus- based 
Standards for the selection of health Measurement Instru-
ments guidelines for measurement properties.21 This 
sample size, however, will be refined after 50% of the data 
collection. Given that the DMOs are measured at walking 
bout level and not at patient level, in this analysis we will 
use the effective number of walking bouts observed during 
the 2.5 hours to perform the power calculation. We will 
base this analysis on a desired Intraclass Correlation Coef-
ficient (ICC) ≥0.7, with Alpha=0.05 and Beta=0.9, and an 
aimed CI of 0.1. Based on this review, more participants 
may be recruited.
Table 2 Inclusion and exclusion criteria adopted for the different disease cohorts
Group Inclusion criteria Exclusion criteria
All groups  ► Able to walk 4 m independently with or without walking 
aids
 ► Able to give informed consent
 ► Willingness to wear the sensor setups during the study
 ► Shoe size 36 European Union (EU) (3 UK) or above
 ► Able to read and write in first language of the 
respective country
 ► Montreal Cognitive Assessment>1555
 ► Available for home /office visit during study period
 ► Occurrence of any of the following 3 months prior 
to inclusion: myocardial infarction, hospitalisation 
for unstable angina, stroke, coronary artery 
bypass graft, percutaneous coronary intervention, 
implantation of a cardiac resynchronisation 
therapy device
 ► Current medical condition that could interfere with 
the patient’s compliance
COPD  ► ≥45 years of age
 ► Diagnosis of COPD (post- bronchodilator forced 
expiratory volume in the first second (FEV
1
) to forced 
vital capacity ratio <0.70)
 ► Clinical stability, defined as at least 4 weeks without 
antibiotics and/or oral corticosteroids to treat either a 
moderate or severe exacerbation
 ► Current or ex- smokers with a smoking history 
equivalent to at least 10 pack years (1 pack year=20 
cigarettes smoked per day for 1 year)
 ► Having undergone major lung surgery (eg, lung 
volume reduction, lung transplant)
 ► Having a lung tumour
 ► Primary respiratory diseases other than COPD (eg, 
asthma)
 ► Impaired mobility related to non- COPD causes, as 
judged by the investigator
PD  ► Aged 18+ years
 ► Diagnosis of PD according to the Movement Disorders 
Society criteria56
 ► Impaired mobility related to non- PD causes, as 
judged by the investigator
MS  ► Aged 18+ years
 ► Diagnosis of MS based on the revised McDonald’s 
criteria
 ► Impaired mobility related to non- MS causes, as 
judged by the investigator
PFF  ► 65+ years of age
 ► Surgical treatment (fixation or arthroplasty) for a 
low- energy fracture of the proximal femur (ICD−10 
diagnosis S72.0, S72.1, S72.2) as diagnosed on X- rays 
of the hip and pelvis within last 12 months
 ► Impaired mobility related to non- PFF causes, as 
judged by the investigator
CHF  ► ≥45 years of age
 ► Diagnosis of chronic heart failure with a grading of II–IV 
of the New York Heart Association Classification
 ► History of COPD≥GOLD III
 ► Impaired mobility related to non- CHF causes, as 
judged by the investigator
HA 65+ years of age   
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HA, healthy older adults; ICD, International Classification of 
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All participants will give written informed consent prior 
to undergoing a clinic/laboratory- based session to record 
generic and disease- specific characteristics. This will 
include participant reported outcomes, assessments and 
medical notes review. The generic and cohort- specific 
clinical outcomes that will be collected are summarised 
in table 3.
Patient and public involvement
Patient and public involvement and engagement has 
informed the design and conduct of this study. The 
protocol and patient facing documents were reviewed 
and changes implemented based on reviewer feedback. 
We will work with our Patient Advisory Group (with 
members representing the patient cohorts involved in the 
study) to review study findings, data interpretation and 
study reporting and dissemination, including codesign 
and presentation of dissemination materials for patients 
and the public. The learnings derived from these activi-
ties will further inform the work of the wider Mobilise- D 
project.
Experimental protocol
Performance of algorithms to determine walking- related 
DMOs is mostly affected by three factors: (1) the type 
of motor task (eg, slow as opposed to fast, straight as 
opposed to curvilinear or inclined walking, etc), (2) the 
population of interest (eg, healthy vs pathological gait), 
(3) the context of observation (eg, home vs outdoors). To 
accommodate these factors, we have developed a compre-
hensive, multistage protocol that includes a variety of 
tests conducted both in a laboratory context and in the 
real world (table 4).
Laboratory-based assessment
Laboratory- based observations will be used to quantify 
validity and consistency within and between groups and 
different types of walking tasks under controlled ideal 
conditions. Structured and task- based mobility activities 
and a simulated daily activity session, mimicking habitual 
movements performed at home or at work will be 
included. The outcome of this comparison will provide 
the level of highest expected accuracy and minimum 
detectable changes for a given DMO.
Measurement tools
Reference system
A stereophotogrammetric (SP) system (100 Hz) will be 
used as the gold standard in structured and simulated 
tests of daily activities to validate the DMOs calculated 
from the DynaPort MM+ raw data. SP systems provide a 
measurement of the instantaneous position of points in 
a 3D measurement volume, by means of a set of cameras, 
each of which can capture the 2D trajectories of markers 
that are attached to the object of interest. The trajectory 
reconstructions are affected by systematic and random 
Table 3 Generic and cohort- specific clinical outcomes
Cohort Generic outcomes
All  ► Descriptive measures (age, sex, living arrangements, 
education)
 ► Anthropometric measures (height, mass, shoe size, waist 
width)
 ► Health status (comorbidities, number of falls and injuries in the 
12 months prior to assessment, walking aid usage and current 
medication)
 ► Montreal Cognitive Assessment to evaluate global cognition55
 ► Visual Analogue Scale to measure pain during walking (0–10, 
from no pain to worse pain possible)
 ► Function component of the Late- Life Function and Disability 
Instrument to evaluate function and disability57 58
Cohort Cohort- specific clinical outcomes
PD  ► Movement Disorder Society- sponsored revision of the Unified 
Parkinson’s Disease (PD) Rating Scale, motor part59
MS  ► Expanded Disability Status Scale*60
COPD  ► 6 min walk test
 ► Recent spirometry test obtained from medical notes to 
characterise lung function*
 ► COPD Assessment Test61
PFF  ► Short Physical Performance Battery—quiet standing balance 
task, a five times chair- raise test, and a 4 m walk test at 
preferred gait speed
CHF  ► 6 min walk test
 ► Kansas City Cardiomyopathy Questionnaire62
*Denotes measures obtained from medical records if completed within 6 months prior 
to assessment.
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; MS, 
multiple sclerosis; PFF, proximal femoral fracture.
Table 4 Summary of the experimental protocol used for the validation of the algorithms in the laboratory and in the real world
Context of assessment Reference systems Tested device Mobility tasks
Laboratory Stereophotogrammetry DynaPort MM+ Structured mobility tasks and daily living 
activities
INDIP   
Real world (2.5 hours) INDIP DynaPort MM+ Unsupervised real- world activities 
(including predetermined tasks)Mobile Phone with
Aeqora App
Beacon
Real world (7 days) Mobile Phone with
Aeqora App
DynaPort MM+ Unsupervised daily living
Beacon   
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instrumental errors, normally minimised to a few milli-
metres via ad hoc calibration procedures and filtering 
and smoothing techniques.22
To ensure quality and consistency in the SP data collec-
tion, accommodating different SP systems across sites, a 
spot check designed following the methodology proposed 
by Di Marco et al23 will be used, which will establish the 
specific level of accuracy for each system. A graphical user 
interface for automated preprocessing of the SP data will 
ensure consistency in associated procedures (labelling, 
gap filling, etc).
A bespoke marker set will be adopted, including four 
markers on each foot for detecting the gait events and 
four markers on the lower back device to track the 
displacement of the DynaPort MM+ device (figure 3).
Tested devices
During this observation each participant will also be 
equipped with an additional multisensor system (INer-
tial module with DIstance Sensors and Pressure insoles, 
INDIP)24–26 and with the Dynaport MM+. The INDIP 
system (figure 4) includes four inertial modules (one on 
the lower back, one on the non- dominant wrist and two 
on the feet), two distance sensors and two force- sensitive 
resistor pressure insoles including 16 force- resistive 
sensing elements (manufacturer 221e S.r.l., Italy). The 
INDIP has been designed to be used as a reference for 
real- world experiments, and in this phase of the protocol 
its performance will be validated against the SP system for 
the populations of interest. Spatio- temporal parameters 
will be estimated exploiting the sensors redundancy and 
implementing previously validated sensor fusion algo-
rithms. Gait events will be detected using data from pres-
sure insoles and inertial sensors independently, and then 
combined to increase robustness and detection accuracy 
(missed and minimisation of extra events). Spatial vari-
ables will be computed from the inertial data of the feet 
using a Madgwick filter27 28 combined with a zero- velocity 
update,29 30 subsequently velocity and displacement will 
be calculated using a direct and reverse approach.24 31–33 
The individual components of the INDIP system and the 
associated algorithms for the estimates of the DMOs have 
already been extensively validated in previous studies on 
various healthy and pathological cohorts.31 34 35 The final 
assembled system in its fully synchronised configuration, 
developed to address the requirements of this study, is 
expected to perform equivalently and as such we can 
anticipate mean absolute percentage errors of 1% on the 
stride duration, between 2% and 3% in the estimate of 
the stride length. Preliminary results from in- lab valida-
tion showed percentage errors of about 2% for gait speed 
as estimated during continuous walking, including both 
straight and curvilinear portions.36
The lower back INDIP unit and the DynaPort MM+ 
will be rigidly attached to each other. The data from the 
SP (100 Hz), INDIP (IMU and insoles, 100 Hz, Distance 
sensor, 50 Hz) and DynaPort MM+ (100 Hz) systems will 
be synchronised using a hardware- based approach for the 
SP and the INDIP system, and timestamps to align record-
ings from the INDIP and the DynaPort MM+.
Mobility tasks
Structured mobility tasks
Straight walking: straight walking is the most common 
test of walking.37 38 The participant walks for a distance 
of 5 m from a standing start and will be repeated at 
three different walking speeds: preferred, fast and slow 
(figure 5A).
Timed Up and Go (TUG): the TUG is a widely used clin-
ical assessment of a person’s mobility.39 The participant 
is asked to sit in a chair, stand up, walk 3 m in a straight 
line, make a 180° turn, walk back to the chair, turn and sit 
down (figure 5B).
L- Test: the participant is asked to sit in a chair, stand 
up, walk straight, turn 90° to the left around a cone, walk 
straight to the second cone, make a 180° turn to the left, 
walk straight before making a final 90° turn to the right 
and return to the chair to sit down (figure 5C). Besides 
being a clinically validated test,40 the main purpose of 
Figure 3 Illustration of the adopted marker set 
configuration. Markers were located on the right (RHEEL) 
and left (LHEEL) heels, toes (RTOE, LTOE) and on the INertial 
module with DIstance Sensors and Pressure insoles (INDIP) 
units located on the right and left foot (RINDIP, LINDIP). Two 
additional reference markers were asymmetrically attached 
to the side of the foot to favour automatic recognition (RREF. 
LREF). Four additional markers were located on the DynaPort 
MM+ sensor (DYNAY, DYNAO, DYNAX, DYNAREF).
Figure 4 Different components of the INertial module with 
DIstance Sensors and Pressure insoles system. The figure on 
the left shows the pressure insoles and the connectors that 
link them to the distance sensors and the inertial modules. 
The picture on the right shows how the same system is then 
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including this test is the variation in curvilinear walking 
and the inclusion of different types of turns.
Two novel additional tests were also included to simu-
late confounding factors that could be encountered in 
the real word:
Surface test: the participant walks around a defined 
circuit by turning around the cones (figure 5D). The 
circuit is completed twice, creating the longest walking 
bout out of all the tasks (approximately 20 m).
Hallway test: the participant walks along a 6 m walkway 
stepping up and down a step positioned in the walkway. 
At the end of the walkway, the participant will complete a 
sharp 180° turn and walk back along the walkway (again 
stepping up and down off the step) until reaching the 
end point of the test (figure 5E).
Daily living activities
These lab- based tasks will be used to simulate daily activi-
ties expected in the real life, similar to previous studies.41 
The participant starts by sitting in chair one and then 
executes a series of daily living tasks while moving around 
the room (see figure 5F,G).
Patients will be given regular opportunities for rest 
periods and will be asked to communicate if they require 
any additional breaks or would like to stop the assessment 
at any point. Use of arm rests for the TUG, L- Test and 
simulated daily living activities, as well as handrails for the 
hallway test are permitted when needed.
Real-world validation (2.5 hours observation)
This phase of the protocol will quantify validity and consis-
tency across individuals and different types of walking 
tasks in the real world. It will be performed in a habitual 
environment (home/work/community/outdoor) 
chosen by the participants, without specific restrictions. 
The duration of the observation has been established as 




Participants will be asked to wear the INDIP, which in this 
phase of the protocol will be used as a reference system 
for the quantification of the DMOs provided by the single 
sensor algorithms, as applied to the DynaPort MM +data.
In order to quantify the effects of contextual 
confounding factors, the participants will also be provided 
with a system detecting outdoors walking, gradient of 
descent/ascent (walking uphill/downhill). The system is 
developed as a mobile Android application (Aeqora app) 
and the device selected was a Samsung S9 with Android 
10. The app is composed of three parts: (1) the core 
tracker, (2) the interface and (3) the server infrastructure 
collecting data across users. The core tracker, adapted 
from a library developed by the University of Sheffield,42 
uses the mobile phone’s internal sensors to compute the 
type of activity (eg, walking) and intensity (eg, cadence) to 
identify geo- located bouts of movement. It operates in the 
background and senses mobility features through a range 
of sensors (eg, step counters, activity recognition, acceler-
ometer, gyroscope, etc) as well as from location services 
(Global Positioning System (GPS), network, Bluetooth, 
etc). It collects the data and stores the raw sensor data 
into a local database in real time. A set of mechanisms 
have been developed to control access to these data, keep 
it secure and regulate its use. First, no user identity infor-
mation is sent within a single request as a token identi-
fier is used. Additionally, a security layer is built based on 
Secure Socket Layer (SSL) and Transport Layer Security 
Figure 5 Diagrams of the selected tasks: (A) straight walking test, (B) timed up and go, (C) L- test, (D) surface test, (E) Hallway 
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(TLS) 3.0 protocol to the data with scalable and efficient 
encryption algorithms. An SSL/TLS certificate is issued 
and used to establish identity and trust between server 
and client apps (desktop and mobile), ensuring privacy 
and security whenever communicating sensitive data.
Data collected during the experiments will be sent to 
a cluster of servers that uses algorithms to integrate the 
phone’s data with contextual information about the loca-
tions where the participant will walk: where possible walks 
will be matched to OpenStreetMap43 roads and paths, 
to remove GPS noise, the slope variation of each walk is 
computed on tiles, with a resolution of 5 m within the 
UK (using Ordnance Survey Terrain 5)44 and 30 m in 
the other locations (using NASA’s Shuttle Radar Topog-
raphy Mission data,45 indoors and outdoors walking is 
recognised. Moreover, weather is associated with partic-
ipant location based on the most proximate weather 
station.
The use of walking aids will also be monitored in this 
phase. For this purpose, a Bluetooth beacon (BlueBeacon 
Tag, BlueUp) will be attached to the walking aid and its 
activity will be detected by the phone’s mobile tracker and 
saved by the app. The distance between the phone and 
the Beacon and data from the accelerometer contained 
in the Beacon will be integrated to determine when the 
aid is in use.
The above contextual factors and the use of walking aids 
will be included in the analyses to determine the extent 
to which they affect variation in the DMOs, although the 
degree of correlation will be adversely affected by the 
issues in accurately measuring context that are associated 
with missing data and GPS accuracy.
Mobility tasks
To capture the largest possible range of activities during 
this assessment, participants will be guided by the 
following list of activities to be included: if relevant for 
their chosen environment, rise from a chair and walk to 
another room; walk to the kitchen and make a drink; walk 
up and down a set of stairs (if possible); walk outdoors 
(if possible, for a minimum of 2 min); if walking outside, 
walk up and down an inclined path. No supervision or 
structure to how these tasks should be completed will be 
given to the participants.
Real-world validation: 7 days monitoring
This observation will quantify the effects of device wearing 
time, hourly and daily fluctuations of DMOs, and contex-
tual confounding factors (such as location of the walk, 
weather, type of housing, etc).
Measurement tools
The participants will be asked to wear the DynaPort MM+, 
and to carry a mobile phone equipped with the Aequora 
App. Bluetooth beacons will also be used to track the use 
of walking aids. The participants will wear the Dynaport 
MM+ at all times (including at night, if willingly). As this 
device is not waterproof, they will be instructed to remove 
it for showering, bathing, using a sauna and swimming 
and reattach it afterwards. They will be asked to keep 
the mobile phone charged, switched on at all times and 
to carry it with them whenever possible, especially when 
leaving the house.
Mobility tasks
Participants will be monitored continuously for 7 days, 
without any specific instruction being provided, except 
for that of wearing the provided measurement tools.
Assessment of participants’ and assessors’ experience
This part of the study will evaluate the participants’ and 
assessors’ experience of using the monitoring device. 
For the participant’s assessment, wear- time of the device 
during the 7 days monitoring will be collected as a 
primary measure of compliance. Following the period 
of the 7 day, free- living data collection, participants will 
complete two questionnaires to assess the acceptability of 
the device. The first is a 12- item questionnaire46 investi-
gating usability on a 5- point ordinal scale. The questions 
are simple and focus on the impact of using a wearable 
device on participants’ feelings, comfort and the ease 
of use of the device. The second questionnaire is the 
Comfort Rating Scale,47 a 6- item measure investigating 
the comfort of a wearable device on a 21- point ordinal 
scale from ‘0—low agreement’ to ‘20—high agreement’.
A subset of participants from all recruiting sites and 
cohorts will complete a semistructured interview (see 
online supplemental file). For this qualitative part of the 
study, sampling will continue until saturation, that is, until 
no additional learning is identified from the data. The 
interview will explore participants’ opinions on the use 
of wearable devices and digital technology in healthcare, 
experiences of managing their condition, experiences of 
technology, and opinions on data privacy associated with 
the use of technology in healthcare. Additionally, partic-
ipants will be asked about their experiences of using the 
device, including comfort, perceived usefulness and ease 
of use, barriers and facilitators, and any other usability 
experiences that they may have encountered. All inter-
views will be audio recorded, transcribed verbatim and, 
where required, translated to English.
To assess the professionals’ experience, assessors 
from each of the clinical sites will be asked to assess the 
usability of the device after completion of the data collec-
tion. They will be provided with three questionnaires: (1) 
the System Usability Scale48 a commonly used, validated 
10- item questionnaire that asks users to rate a device on 
a 5- point Likert scale from ‘1 strongly disagree’ to ‘5—
strongly agree’. Questions focus on the ease of use of the 
device, and the integration of various functions within it; 
(2) the IBM Computer System Usability Questionnaire49 
(to assess the DynaPort MM+ software), is composed of 19 
items and asks respondents to consider their interaction 
with a computer system on a 7- point Likert scale from 
the perspective of data collection; (3) a bespoke ques-
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Table 5 List of digital mobility outcomes (primary and secondary digital mobility outcomes (DMOs)) that will be analysed as 
part of the technical validation study
Variables DMOs (units) Definition DMO attainable
      DynaPort MM+ SP System INDIP Aeqora App
Walking bout (WB)
A walking sequence 
containing at least two 
consecutive strides of 
both feet. Start and end 
of a WB are determined 
by a resting period or any 
other activity (non- walking 
period).
Number of WBs 
(count)
Based on the 
identification of gait as 
an activity (yes/no) to a 
sample level of 0.1 s
✓ ✓ ✓ ✓
WB start (s) Start of WB ✓ ✓ ✓
WB end (s) End of WB ✓ ✓ ✓
WB duration (s) Time between start and 




Refers to the duration 
(time intervals) of strides/
steps, calculated as the 
time in between two non- 
consecutive (alternate) 
initial contacts.
Stride duration (s) Duration between 
two non- consecutive 
(alternate) initial contact 
events
✓ ✓ ✓
Step duration (s) Duration between two 
consecutive initial contact 
events
✓ ✓ ✓
Cadence (CE) Cadence (steps/
min)
Steps performed within a 
minute
✓ ✓ ✓
Stride length (SL) Mean stride length 
(m)







Velocity, average stride 
speed within a WB
✓ ✓ ✓ ✓
Turning Number of turns Overall number of turns 
performed in a WB based 
on the identification of 
turns (yes/no) to a sample 
level of 0.1 s
✓ ✓ ✓
Turn start (s) Start of each turn within 
the WB
✓ ✓ ✓
Turn end (s) End of each turn within 
the WB
✓ ✓ ✓
Turn duration (s) Time between the start 
and the end of the turns 
within the WB
✓ ✓ ✓
Maximal turn angle 
(deg)
Maximal angle achieved 
in the turn
✓ ✓ ✓
Height estimation Elevation change 
(m)
Difference between the 
minimal and maximal 
height or elevation for 
the complete walking 
bout detected for incline 
walking
✓ ✓ ✓ ✓
Left/Right identification Laterality (label) Left or right category, 
indicating the foot with 





Number of final 
contact events 
(counts)
Correct identification of 
final contact events
✓ ✓ ✓
Final contact event 
(s)
Instant of time at which 
each final contact event 
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acceptability and effectiveness of the training methods, 
procedures and any other materials provided within the 
study. The questionnaire will ask respondents to rate 
their experiences on a 7- point Likert scale to determine 
whether any changes to the procedures and materials are 
required, and whether training was effective in preparing 
assessors to implement the assessment protocol as 
planned.
In addition, assessors will complete a semistructured 
interview with the aim of exploring their experiences of 
the data collection process. Assessors will be asked about 
the use of the device (eg, ease of use, intuitiveness, data 
collection and download procedures, etc), training and 
materials provided prior to the commencement of the 
study, and barriers and facilitators to using the device. 
The topic guide and open- ended questions allow for new 
areas of conversation to emerge. All interviews will be 
audio- recorded and transcribed verbatim.
Data management
All data will be uploaded to a central platform ‘e- Science 
Central’ (e- SC)50 which provides data processing and 
storage functionality in accordance with principles of 
reproducible research. The underlying infrastructure 
complies with the International Organization for Stan-
dardization (ISO 27000) standards for Information 
Security Management Systems and is hosted on Amazon 
Web Service secure services cloud platform. Data will be 
integrated on the platform by means of implementation 
of a standardised file nomenclature system. At point of 
capture, each file will be labelled in standardised format. 
For source data, we will adhere to principles defined 
by the US Food and Drug Administration51 for making 
them attributable, legible, contemporaneous, original 
and accurate. In particular, we will use both web- based 
forms on e- SC and an application from ERT (partner in 
the project) to capture the electronic clinical outcome 
assessments. The e- SC forms provide storage of event 
data, and support for data validation and basic data entry 
and verification. Both e- SC and ERT systems employ error 
handling at source which alert the assessors of incorrect 
data entry (eg, min/max boundaries, required/optional 
fields). Data captured at source on paper will be copied, 
signed and scanned, then uploaded to e- SC as a certified 
copy. The motion capture data will also be transferred to 
e- SC and stored in an unmodified form. These data will 
be either uploaded directly to e- SC via the e- SC portal or 
transferred via an Application Programming Interface. 
The algorithms being developed and benchmarked will 
be used to process these files and extract and store the 
DMOs.
Data analysis plan
Verification of the device
Mean and SD readings of the accelerometer, gyro-
scope and magnetometer signals captured during static 
Variables DMOs (units) Definition DMO attainable
Swing phase 
duration (s)
Time between the last 
contact of the current 
footfall and the first 
contact of the next 




Time in between the 
first contact and the 
last contact of two 
consecutive footfalls on 
the same foot
✓ ✓ ✓
Variability of: step 
time, stride time, 
swing time, stance 
time stride velocity 
stride length
(same units as 
variable)
St. Dev. and Coefficient 
of Variation of step time, 
of stride time, of swing 
time, of stance time, of 
stride velocity and stride 
length within a WB
✓ ✓ ✓
Asymmetry of: step 
time, stride time, 
swing time, stance 
time
(same units as 
variable)
Asymmetry evaluated as 
difference between right 
and left steps or strides 
for step time, of stride 
time, of swing time and of 





WB completed in an 





Walking aid assistance 
during WB
✓ ✓











































































































































































Table 6 List of statistical analyses and performance metrics that will be used for the various digital mobility outcomes (DMOs)
DMO
































✓ ✓ ✓ ✓ ✓
WB start ✓ ✓ ✓ ✓ ✓ ✓ ✓
WB end ✓ ✓ ✓ ✓ ✓ ✓ ✓
WB duration ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Initial contact 
events
✓ ✓ ✓ ✓
Step duration ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Stride 
duration
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Final contact 
events
✓ ✓ ✓ ✓
Mean stride 
length
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Cadence ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Elevation 
change
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Walking 
speed
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Number of 
turns
✓ ✓ ✓ ✓ ✓
Turn start ✓ ✓ ✓ ✓ ✓ ✓ ✓
Turn end ✓ ✓ ✓ ✓ ✓ ✓ ✓
Turn duration ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Maximal Turn 
angle
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓




Performance metrics and criterion validity are those that will be used to compare DMOs obtained from a single device versus those obtained from the reference system. The types of plots listed in the table will be used to visualise performance 
metrics and to support interpretation of the results.
ICC, intraclass correlation coefficients; WB, walking bouts.
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acquisition will be used to assess the reliability of the 
manufacturer sensor calibration and to detect the pres-
ence of abnormal spikes in the sensor signals. Data from 
long static acquisitions will be used to confirm the stability 
of sampling frequency, the duration of the battery, and to 
estimate the Allan deviation (bias instability) of the gyro-
scope readings over time. Errors of gyroscope readings 
will be assessed using mean and SD of nominal, measured 
and relevant errors for angular velocity values during the 
dynamic acquisitions.
Validation of the algorithms
The data analysis will determine criterion validity 
(including selected performance metrics and criterion 
(concurrent) validity metrics of the primary (real- world 
walking speed) and secondary DMOs listed in table 5. 
Table 6 summarises the statistical tools that will be used 
to quantify each of the DMOs. All statistical analyses 
will be performed using the statistical analysis toolbox 
of Matlab R2018a. In all tasks and observations, contin-
uous variables (eg, cadence, real- walking speed) will 
be summarised with descriptive statistics for the values 
obtained within walking bouts (mean and SD). ICC and 
its CI (95% CI) will be provided. In addition, the mean, 
minimum, maximum, SD, median, IQR and root mean 
square error of DMOs over all available walking bouts will 
be presented. Categorical variables (eg, laterality of initial 
contacts) will be summarised with frequency counts and 
percentages.
Using the gold standard as a reference, true positives 
(TP), false positives (FP), true negatives (TN) and false 
negatives (FN) will be identified for the DMOs identified 
from the single device using a cut- off tolerance window 
defined as a fixed interval of 0.5 s52 and centred on each 
event detected by the reference system. The following 














F1score = 2 ∗ Positive Predicted Value∗SensitivityPositive Predicted Value+Sensitivity 
Criterion validity will be characterised by evaluating the 
absolute and relative errors, defined as the relative and 
absolute differences between the DMOs quantified with 
the single device and those derived from the reference 
systems:




DMO estimated by IMU−DMO estimated by Reference System





 Absolute Error = | DMO estimated by IMU − DMO estimated by Reference System | 
The mean, SD and maximum of all errors will be 
reported for each walking bout. Limits of agreement 
between single sensor and reference system DMOs will 
be quantified. In addition, statistically significant differ-
ences between the DMOs quantified by the IMU and 
those by the reference system, parametric (paired t- test) 
or non- parametric (Wilcoxon signed- rank test) tests will 
be performed depending on the normality of the distri-
bution of the DMOs. Data distribution will be visually 
inspected with histograms, and normality tested with the 
Shapiro- Wilk test.
Concurrent validity between the DMOs quantified by the 
single device and those derived from the reference systems 
will be evaluated by quantifying the Intraclass Correlation 
Coefficient (eg, ICC (2,1)).
All results will be presented separately by cohort (eg, PD) 
and subgroup (ie, subgroups of the cohorts) stratified by 
average stride gait speed (eg, fast speed: walking speed >1 
m/s, medium speed: walking speed between 0.5 m/s and 1 
m/s, slow speed: walking speed <0.5 m/s).2
If participants do not participate in one assessment (eg, 
one of the tasks in the laboratory) or observation (eg, 2.5 hs), 
their remaining available data corresponding to remaining 
assessments/observations will still be included in the anal-
yses. Within each of the contexts/assessments/observations, 
and assuming that data are missing completely at random, a 
complete case approach will be used to handle missing data.53
Participants’ and assessors’ experience
Participant and professional questionnaire data will be anal-
ysed using descriptive statistics. Interviews will be analysed 
using thematic analysis.54 Transcripts will be deductively 
examined for the presence of themes related to the accept-
ability of the monitoring device to participants (ie, comfort, 
interference with daily living) based on previous literature. 
Specifically, perceived usefulness, comfort and ease of use 
are critical factors of usability; thus, these will be the catego-
ries examined within the transcripts. Regarding participants 
use of technology to manage their healthcare condition, an 
inductive approach will be taken. A list of codes relevant to 
the question will be generated and then refined by grouping 
them into potential themes.
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Mobilise-D Technical Validation Study 
Participant interview topic guide  
 
Interview guide  
 
Note: Questions in this topic guide are included to answer the above aims. If the participant is open 
and talks freely, they may answer some of the questions without being asked. Therefore, depending 
on the person, not all of these questions need to be asked. If they begin to talk about topics that may 
be interesting or relevant to the above aims, please feel free to continue to explore these, even if 
there is no specific question linked to it. In contrast, if participants are not very open, some potential 
prompts have been included with the questions below. These prompts are there as an optional guide 
and do not need to be used.   
 
Dynaport questions 
Aim: Ensure that the McRoberts Dynaport device is comfortable and acceptable to participants 
Main questions 
1 Can you describe your experience of using the Dynaport sensor in the last week? 
2 Can you tell me what you liked about the device? Disliked? 
Prompts if needed 
- Size/weight 
- Attachment to body 
- Ease of use 
- Comfort 
3 How did the device make you feel? / Can you describe what it felt like to wear the device? 
Prompts if needed 
- In social environments/at home 
- Interaction with daily activities  
- Emotions associated with being monitored 
4 What you change about the device if you could?  
Follow-up questions 
“If you don’t mind, I’d like to ask you some specific details about the device.” 
1 How did you find the process of putting it on and taking it off? 
2 How did the device influence your daily activities?  
Prompts if needed 
- How were they impacted? 
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- How did this make them feel? 
3 Can you tell me about any difficulties that you had with the device?  
4 How did you feel about wearing the device for a week? 
Prompts if needed 
- How would they feel if it was longer? 
- Any concerns for the week? 
Closing question 
1 Is there anything else you would like me to know about the Dynaport? 
 
 
The use of wearable devices in healthcare questions 
Aim: Explore the acceptability of wearable devices, for the purposes of healthcare monitoring, to 
participants in general.  
Main questions 
1 Can you tell me about your experience of your health condition? 
Note: Condition specific symptoms are listed at the end of this document. 
2 Can you tell me about your experience of the care you’ve received for your condition? 
Prompts if needed 
- How do they feel about it? 
3 Can you tell me about what sort of technology you currently use in your everyday life? 
Prompts if needed 
- How do you feel about using technology? 
- What would make you use technology more? Less? 
- Emotions associated with being monitored 
4 What are your opinions on the use of technology in healthcare? 
Prompts if needed 
- What do you think it can be used for? 
5 How would you feel about using technology to generate health information about 
yourself? (e.g. condition related smartphone app, self-reported outcomes platform, 
fitness tracker etc.),  
Prompts if needed 
- Why? 
- What would make you use it? 
- What would stop you from using it? 
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- What would need to change for you to use it? 
Follow-up questions 
1 How do you feel about capturing health information in your daily life, using a wearable 
remote monitoring device? 
2 How do you think digital technology used in your daily life would influence how you manage 
your condition? 
Prompts if needed 
- How would it impact their relationship with their health care provider? 
- Integration into activities of daily living 
3 How would you feel about sharing this data with your health care provider? What about 
researchers? 
Prompts if needed 
- Usefulness  
- Impact of this 
Closing question 







The System Usability Scale  
To be completed by researchers who have collected data using the McRoberts device. When 
answering these questions please consider how you personally have found the McRoberts device, 
not how the participants have found it. 
 
 1  
strongly 
disagree 
2 3 4 5  
strongly 
agree 
I think that I would like to use this system frequently.      
I found the system unnecessarily complex.      
I thought the system was easy to use.      
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I think that I would need the support of a technical 
person to be able to use this system. 
     
I found the various functions in this system were well 
integrated. 
     
I thought there was too much inconsistency in this 
system. 
     
I would imagine that most people would learn to use 
this system very quickly. 
     
I found the system very cumbersome to use.      
I felt very confident using the system.      
I needed to learn a lot of things before I could get 
going with this system. 
     
I think that I would like to use this system frequently.      
 
 





The IBM Computer System Usability Questionnaire  
To be completed by researchers who have collected data using the McRoberts device. When 
answering these questions please consider how you personally have found the McRoberts device, 
not how the participants have found it. 
 
 1  
strongly 
disagree 





Overall, I am satisfied with how easy it is to use 
this system.  
       
It is simple to use this system.         
I can effectively complete my work using this 
system.  
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I am able to complete my work quickly using 
this system.  
       
I am able to efficiently complete my work using 
this system.  
       
I feel comfortable using this system.         
It was easy to learn to use this system.         
I believe I became productive quickly using this 
system.  
       
The system gives error messages that clearly 
tell me how to fix problems.  
       
Whenever I make a mistake using the system, I 
recover easily and quickly.  
       
The information (such as on-line help, on-
screen messages and other documentation) 
provided with this system is clear.  
       
It is easy to find the information I need.         
The information provided with the system is 
easy to understand.  
       
The information is effective in helping me 
complete my work.  
       
The organization of information on the system 
screens is clear.  
       
The interface of this system is pleasant.         
I like using the interface of this system.         
This system has all the functions and 
capabilities I expect it to have.  
       
 
 
Intervention specific questionnaire  
This questionnaire aims to evaluate your experiences and opinions on the processes of the Mobilise-
D technical validation study. In particular, we are looking to focus on the components of the study 
which will also take place within the clinical validation trial.  Therefore, when asking about certain 
aspects of the trial, we may be specific in relation to which device or measurement tool we want 
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feedback on. Please read each question carefully to ensure that your answers relate to the specific 
component under investigation.  
The purpose of this questionnaire is to determine your opinions on i) the training you received, ii) 
the supporting materials that were provided to you, iii) the feasibility of conducting participant 




When considering training, we want you to consider the training that you received to carry out the 
following: 
- Recruit participants 
- Complete the human factors assessment  
- Use the McRoberts device  
- Use the ERT platform 
- Use the EScience platform 
 
Many of these training components would have been delivered separately. We want you to consider 
your experience on these training sessions overall, and then answer questions for each specific 
component independently. There is space to write comments at the end of this section if you wish to 
add more information or clarify any aspect further. 
 

















The Mobilise-D training 
programme was enjoyable  
      
The Mobilise-D training 
programme was useful 
      
The Mobilise-D training 
programme successfully 
prepared me to collect data 
within the technical 
validation trial 
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The Mobilise-D training 
programme successfully 
prepared me to recruit 
participants within the 
technical validation trial 
      

















The training was sufficiently 
interactive 
      
The training was interesting        
The training was easy to 
understand 
      
The training provided a clear 
outline of what was expected 
from me 
      
The training provided a clear 
rationale of recruitment 
processes 
      

















I felt confident in my 
recruitment role following 
training  
      
I felt competent to complete 
recruitment following 
training  
      
Following training, I had no 
questions regarding 
recruitment 
      
Following training I was 
confident in who I should 
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contact if I had a question 
regarding recruitment 



















I felt confident in my data 
collection role following 
training  
      
I felt competent to complete 
data collection following 
training  
      
Following training, I had no 
questions regarding data 
collection 
      
Following training I was 
confident in who I should 
contact if I had a question 
regarding data collection 
      



















I felt confident in using 
McRoberts following training  
      
I felt competent to complete 
data collection with 
McRoberts following training  
      
Following training, I had no 
questions regarding the 
McRoberts device 
      
Following training I was 
confident in who I should 
contact if I had a question 
regarding McRoberts 
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I felt confident in the use of 
the ERT platform following 
training  
      
I felt competent to complete 
data collection using ERT 
following training  
      
Following training, I had no 
questions regarding the ERT 
platform 
      
Following training I was 
confident in who I should 
contact if I had a question 
regarding the ERT platform 
      
 
 
Please provide us with any further feedback you have regarding the training that you undertook as 
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Project materials feedback  
As part of the Mobilise-D project, you received a number of materials to help support you in the 
recruitment and data collection processes (i.e. manuals, etc). Please provide us with your feedback 
on these items  
 

















The recruitment materials 
were easy to understand  
      
I used the recruitment 
materials a lot to help me 
recruit participants 
      
As recruitment progressed I 
used the materials less   
      
The materials answered all 
my recruitment questions  
      
The materials made the 
recruitment process easier  
      
When I used the materials I 
felt more confident in the 
recruitment process 
      

















The data collection materials 
were easy to understand  
      
I used the data collection 
materials a lot to help me 
recruit participants 
      
As data collection progressed 
I used the materials less   
      
The materials answered all 
my data collection questions  
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The materials made the data 
collection process easier  
      
When I used the materials I 
felt more confident in the 
data collection process 
      
 
Please provide us with any further feedback you have regarding the materials that you received as 









Feasibility of the trial procedures  
 
Recruitment  
How many participants did your site recruit?  
How many participants was your site due to recruit? 
What barriers to participant recruitment did you encounter? 
What helped you to recruit people?  
What additional materials do you believe would help support recruitment in the future? 
What additional support do you believe would help support recruitment in the future? 
 
Data collection 
How many participants failed to complete full data collection procedures? 
Why? 
What additional materials do you believe would help support data collection in the future? 
What additional support do you believe would help support data collection in the future? 
Do you have any other thoughts regarding the recruitment and data collection procedures of the 
Mobilise-D technical validation trial? 
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Start with a general question about how they found the experience of data collection within 
the Mobilise-D validation study 
 
The Dynaport device 
• Tell me about how you found using the Dynaport sensor during the trial? 
• What were your first impressions of the device? 
• Can you tell me what you liked about the device? Disliked?  
• Can you tell me about any difficulties that you had with the device or its platform 
during the trial?  
o Difficulties they encountered themselves 
▪ Set up 
▪ Ease of explanation for participants 
o Difficulties that were reported to them 
▪ Did participant get in contact during the week? 
▪ Did any devices come back damaged? 
• How would you compare this device to other wearables that you have used before?  
 
The ERT device  
• Tell me about how you found using the ERT platform during the trial? 
• What were your first impressions of the device? 
• Did any of your opinions change as the trial progressed? 
• Can you tell me what you liked about the device? Disliked?  
• Can you tell me about any difficulties that you had with the device during the trial?  
• How did the device make you feel? 
 
The EScience platform 
• Tell me about how you found using the EScience platform during the trial? 
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• What were your first impressions of the platform? 
• Did any of your opinions change as the trial progressed? 
• Can you tell me what you liked about the platform? Disliked?  
• Can you tell me about any difficulties that you had with the device during the trial?  
 
 
The training and materials used 
• Can you tell me what your opinions are of the training you received before starting 
data collection? 




o Materials provided 
• What did you expect to get out of the training? 
• What was useful about the training? Not useful? 
• Describe how you found the process of data collection? 
• How did this compare to what you expected following training? 




Can you tell me about your experiences recruiting participants for the Mobilise-D trial 
What needs to change to make recruitment easier? 
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